Divis Laboratories (DIVISLAB.NS) Financial Analysis & Valuation | Quarter Chart
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (APIs) and intermediates, and nutraceutical ingredients in India, the United States, Asia, Europe, and internationally. It also undertakes custom synthesis of APIs and intermediates; and supplies a rang... more
Divi's Laboratories Limited manufactures and sells generic active pharmaceutical ingredients (A... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $25.60B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | IN | CEO | Kiran Satchandra Divi |
| IPO Date | 2003-03-12 | CAGR | 17.66% |
| Employees | 11,565 | Website | www.divislabs.com |
| Div. Yield | 0.05% | Payout Ratio | 27% |
| Buy Back Yield | — | Total Yield | 0.05% |
DIVISLAB.NS chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $20.02B | P/E | 84.79 | Forward P/E | 61.81 | PEG | 1.29 |
| P/S | 233.67 | P/B | 156.81 | P/CF | 1595.21 | P/FCF | 25981.33 |
| Sales | $1.18B | Sales 1Y | 16.77% | Sales 3Y | 56.18% | Sales 5Y | 58.43% |
| EPS | $1.14 | EPS 1Y | 26.86% | EPS 3Y | 98.02% | EPS 5Y | 42.77% |
| Sales QoQ | 8.8% | EPS QoQ | 20.03% | Sales QoQ Avg | 6.52% | EPS QoQ Avg | 14.98% |
| Gross Margin | 49.85% | Operating Margin | 31.02% | Profit Margin | 26.05% | ROCE | 19.36% |
| ROA | 15% | ROE | 19% | Altman Z Score | 42.19 | Piotroski Score | 3 |
| Current Ratio | 5.43 | Quick Ratio | 3.5 | Cash Ratio | 1.67 | Op. CF Ratio | — |
| Debt/Equity | 0 | Debt/Assets | 0 | Lt Debt/Equity | 0 | Lt Debt/Cap. | — |
| Intrst Cov. | 133.96 | Inventory Turnover | 1.42 | Asset Turnover | 0.56 | Receivables Turnover | 3.76 |
| Enterprise Value | $20.02B | P/E Ratio | 84.79 |
| Forward P/E | 61.81 | PEG Ratio | 1.29 |
| P/S Ratio | 233.67 | P/B Ratio | 156.81 |
| P/CF Ratio | 1595.21 | P/FCF Ratio | 25981.33 |
| EPS | $1.14 | EPS Growth 1Y | 26.86% |
| EPS Growth 3Y | 98.02% | EPS Growth 5Y | 42.77% |
| Revenue Growth 1Y | 16.77% | Gross Margin | 49.85% |
| Operating Margin | 31.02% | Profit Margin | 26.05% |
| ROE | 19% | ROA | 15% |
| ROCE | 19.36% | Current Ratio | 5.43 |
| Quick Ratio | 3.5 | Cash Ratio | 1.67 |
| Debt/Equity | 0 | Interest Coverage | 133.96 |
| Altman Z Score | 42.19 | Piotroski Score | 3 |
Divis Laboratories (DIVISLAB.NS) valuation & financials
Divis Laboratories (DIVISLAB.NS) has a market capitalization of $25.60B and trades at a price-to-earnings ratio of 84.8. It operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic).
Divis Laboratories's revenue grew +16.8% over the last year.
Divis Laboratories's next earnings report is scheduled for November 9, 2026 (provider scheduled date); analysts estimate EPS of $0.33. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)